Leslie A. Spikes
Expertise in
7
conditions

Dr. Leslie A. Spikes

Pulmonary Medicine
2000 Olathe Boulevard, 
Kansas City, KS 
Accepting New Patients
Offers Telehealth
Referral required
Before you request
Expertise in
7
conditions
2000 Olathe Boulevard, 
Kansas City, KS 

Overview

Leslie Spikes is a Pulmonary Medicine provider practicing medicine in Kansas City, Kansas.

Dr. Spikes is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Acute Interstitial Pneumonia, Lung Metastases, and Endoscopy.

Dr. Spikes is board certified in American Board Of Internal Medicine, Pulmonary Disease - 2009 and American Board Of Internal Medicine, Critical Care Medicine - 2010 . She is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 18 clinical trials. Dr. Spikes is currently accepting new patients.

Specialties

Pulmonary Medicine

Licenses

Internal Medicine in KS

Board Certifications

American Board Of Internal Medicine, Pulmonary Disease - 2009
American Board Of Internal Medicine, Critical Care Medicine - 2010

Fellowships

University of Kansas Medical Center, Pulmonary Medicine and Critical Care Medicine, 2010

Hospital Affiliations

University Of Kansas Health System Olathe Hospital
Kansas City Orthopaedic Institute
University Of Kansas Hospital
Stormont Vail Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Medical Pavilion
2000 Olathe Boulevard, Kansas City, KS 66160
Other Locations
The University of Kansas Hospital
4000 Cambridge Street, Kansas City, KS 66160

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase 2b, Open-label, Single Dose Study to Evaluate the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects With Pulmonary Arterial Hypertension (PAH)
A Phase 2b, Open-label, Single Dose Study to Evaluate the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects With Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Completed
Publish Date: July 13, 2026
Intervention Type: Combination product
Study Drug: RT234
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
Enrollment Status: Terminated
Publish Date: June 08, 2026
Intervention Type: Other, Drug
Study Drug: Sotatercept
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk Mortality
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk Mortality
Enrollment Status: Completed
Publish Date: May 29, 2026
Intervention Type: Other, Drug
Study Drug: Sotatercept
Study Phase: Phase 3
Post COVID-19 Biorepository
Post COVID-19 Biorepository
Enrollment Status: Active_not_recruiting
Publish Date: May 22, 2026
COVID-19 Biorepository
COVID-19 Biorepository
Enrollment Status: Active_not_recruiting
Publish Date: May 22, 2026
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Completed
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drug: Sotatercept
Study Phase: Phase 2
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Rodatristat Ethyl
Study Phase: Phase 2
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Drug
Study Drug: Treprostinil Inhalation Powder
Study Phase: Phase 1
View 9 Less Clinical Trials

13 Total Publications

Targeting pathogenic VWF/ADAMTS13 dysregulation attenuates CTEPH progression.
Targeting pathogenic VWF/ADAMTS13 dysregulation attenuates CTEPH progression.
Journal: bioRxiv : the preprint server for biology
Published: July 03, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Mark J. Hamblin
Pulmonary Medicine
Expertise in
17
conditions
Dr. Mark J. Hamblin
Pulmonary Medicine
Referral may be required
Before you request

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
 (0.1 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Hamblin is a Pulmonary Medicine provider practicing medicine in Kansas City, Kansas. Dr. Hamblin is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Interstitial Lung Disease, Acute Interstitial Pneumonia, Pulmonary Fibrosis, Sarcoidosis, and Bone Marrow Aspiration. Dr. Hamblin is board certified in American Board Of Internal Medicine, Pulmonary Disease - 2011 and American Board Of Internal Medicine, Critical Care Medicine - 2012 . Dr. Hamblin is currently accepting new patients.

Expertise in
9
conditions
Dr. Scott M. Matson
Pulmonary Medicine
Expertise in
9
conditions
Dr. Scott M. Matson
Pulmonary Medicine
Referral may be required

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
 (0.1 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Matson is a Pulmonary Medicine provider practicing medicine in Kansas City, Kansas. Dr. Matson is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Interstitial Lung Disease, Acute Interstitial Pneumonia, Rheumatoid Lung Disease, and Pulmonary Fibrosis. Dr. Matson is board certified in American Board Of Internal Medicine, Internal Medicine - 2016, American Board Of Internal Medicine, Pulmonary Disease - 2019 , and American Board Of Internal Medicine, Critical Care Medicine - 2020 . Dr. Matson is currently accepting new patients.

Expertise in
12
conditions
Dr. Lucas R. Pitts
Pulmonary Medicine
Expertise in
12
conditions
Dr. Lucas R. Pitts
Pulmonary Medicine
Referral may be required
Before you request

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
 (0.1 miles away)
913-588-1227
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Lucas Pitts is a Pulmonary Medicine provider practicing medicine in Kansas City, Kansas. Dr. Pitts is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Sarcoidosis, Acute Interstitial Pneumonia, Hypersensitivity Pneumonitis, Endoscopy, and Bone Marrow Aspiration. Dr. Pitts is board certified in AABIP American Assoc For Bronchology & Interven Pulmonology, - - 2024 , American Board Of Internal Medicine, Pulmonary Disease - 2010, and American Board Of Internal Medicine, Critical Care Medicine - 2011 . Dr. Pitts is currently accepting new patients.

Frequently Asked Questions about Dr. Leslie A. Spikes

How do I make an appointment with Dr. Leslie A. Spikes?

You can book an appointment with Dr. Leslie A. Spikes by calling their office at 913-588-1227. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Leslie A. Spikes a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Leslie A. Spikes is classified as an Elite expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Leslie A. Spikes specialize in?

While Dr. Leslie A. Spikes is a Pulmonary Medicine, they have specific expertise in Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, and Acute Interstitial Pneumonia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. Leslie A. Spikes participate in research or clinical trials?

Yes. Dr. Leslie A. Spikes has published 13 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Dr. Leslie A. Spikes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Leslie A. Spikes accept my insurance?

Dr. Leslie A. Spikes accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 913-588-1227 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Spikes's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile